168 related articles for article (PubMed ID: 12658024)
1. Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
Peters H; Rückert M; Gaedeke J; Liefeldt L; Ketteler M; Sharma AM; Neumayer HH
J Hypertens; 2003 Apr; 21(4):771-80. PubMed ID: 12658024
[TBL] [Abstract][Full Text] [Related]
2. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH
Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Peters H; Border WA; Noble NA
Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
[TBL] [Abstract][Full Text] [Related]
4. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
Yu L; Border WA; Anderson I; McCourt M; Huang Y; Noble NA
Kidney Int; 2004 Nov; 66(5):1774-84. PubMed ID: 15496148
[TBL] [Abstract][Full Text] [Related]
5. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Peters H; Border WA; Noble NA
Kidney Int; 1998 Nov; 54(5):1570-80. PubMed ID: 9844133
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis.
Peters H; Eisenberg R; Daig U; Liefeldt L; Westenfeld R; Gaedeke J; Krämer S; Neumayer HH
Kidney Int; 2004 Jun; 65(6):2238-48. PubMed ID: 15149337
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
8. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis.
Gaedeke J; Boehler T; Budde K; Neumayer HH; Peters H
Nephrol Dial Transplant; 2005 Feb; 20(2):319-28. PubMed ID: 15673690
[TBL] [Abstract][Full Text] [Related]
9. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
[TBL] [Abstract][Full Text] [Related]
10. Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.
Zhang J; Gu C; Noble NA; Border WA; Huang Y
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F723-32. PubMed ID: 21795644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
Ciechanowicz A
Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.
Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
15. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
Hartner A; Hilgers KF; Bitzer M; Veelken R; Schöcklmann HO
J Mol Med (Berl); 2003 Jan; 81(1):32-42. PubMed ID: 12545247
[TBL] [Abstract][Full Text] [Related]
16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
[TBL] [Abstract][Full Text] [Related]
17. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
Volpini RA; da Silva CG; Costa RS; Coimbra TM
Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
[TBL] [Abstract][Full Text] [Related]
19. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Peters H; Border WA; Noble NA
Kidney Int; 2000 Mar; 57(3):992-1001. PubMed ID: 10720952
[TBL] [Abstract][Full Text] [Related]
20. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
Huang Y; Haraguchi M; Lawrence DA; Border WA; Yu L; Noble NA
J Clin Invest; 2003 Aug; 112(3):379-88. PubMed ID: 12897205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
